Gennex Laboratories Ltd. (BSE: 531739) is a Hyderabad, Telangana-based company in the Pharmaceuticals industry. With a market capitalisation of ₹219 Cr, it ranks #2,583 by market cap among the 6,137 Indian listed companies on FinBizNet, and #35 of 63 in Pharmaceuticals. At ₹8.70 (as of 25 Oct 2026), the share price is 49.6% below its 52-week high of ₹17.25 and 23.4% above its 52-week low of ₹7.05. The share price is down 37.5% over one year and down 4.2% over three months.
| Current Price | ₹8.70 |
|---|---|
| Market Cap | ₹219 Cr |
| BSE Code | 531739 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 10.3 |
| Return on Equity | 9.82% |
| Return on Assets | 4.11% |
| 52-Week Range | ₹7.05 – ₹17.25 |
| 1-Year Price Change | -37.5% |
| 3-Month Price Change | -4.2% |
| Beta (1Y) | 1.12 |
| Headquarters | Hyderabad, Telangana |
| Website | www.gennexlab.com |
Gennex Laboratories Limited manufactures and sells bulk drugs, intermediates, and biotech products. The company offers Guaifenesin, an expectorant used as a mucolyte; Methocarbamol for skeletal muscle relaxant; Fexofenadine Hcl for treating antihistamines; Phenazopyridine Hcl for the treatment of urinary tract analgesic; Fluconazole for antifungals; Melitracen Hcl for treating tricyclic antidepressant; Sertraline Hcl, a selective serotonin reuptake inhibitor; Chlorphenesin and Mephenesin for muscle relaxant; and Allopurinol, a xanthine oxidase inhibitor. It has operations in India, Algeria, Bangladesh, Barzil, Bolivia, Colombia, the Czech Republic, Egypt, El Salvador, Germany, Guatemala City, Mexico, Peru, Spain, Turkey, Thailand, the United Arab Emirates, and Vietnam. Gennex Laboratories Limited was formerly known as Prudential Pharmaceuticals Limited and changed its name to Gennex Laboratories Limited in September 2007. Gennex Laboratories Limited was incorporated in 1985 and is base
1. Bulk Drugs,Biotech Products and Intermediates-This segment manufactures bulk drugs, intermediates, and biotech products. 2. Other-0 3. Segment Adjustment-0
1. Bulk Drugs, Biotech Products and Intermediates-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹55,577 Cr | 35.5 | 34.46% | ₹1,814 Cr | -16.1% |
| Ajanta Pharma Limited | ₹41,591 Cr | 39 | 25.39% | ₹1,626 Cr | +36.3% |
| Emcure Pharmaceuticals Ltd | ₹34,533 Cr | 36.3 | 19.57% | ₹2,580 Cr | +31.1% |
| Piramal Pharma Ltd | ₹26,284 Cr | -79 | -4.00% | ₹2,270 Cr | -1.6% |
| RUBICON RESEARCH LIMITED | ₹24,972 Cr | 97.6 | 19.14% | ₹534 Cr | — |
| Caplin Point Laboratories Ltdte | ₹17,484 Cr | 26.9 | 19.94% | ₹610 Cr | +10.3% |
| Pfizer Ltd. | ₹17,448 Cr | 24.1 | 17.16% | ₹653 Cr | -32.1% |
| Eris Lifesciences Ltd | ₹15,877 Cr | 24.8 | 18.07% | ₹873 Cr | -30.8% |
| Gennex Laboratories Ltd. | ₹219 Cr | 10.3 | 9.82% | — | -37.5% |
Listed by market capitalisation. Ratios are shown for context only.
Gennex Laboratories Ltd. is trading at ₹8.70, with a market capitalisation of ₹219 Cr.
Gennex Laboratories Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Gennex Laboratories Ltd. has a P/E of 10.3 and a return on equity of 9.82%.
Gennex Laboratories Ltd. is listed on the BSE under the scrip code 531739.
Gennex Laboratories Ltd.'s share price is down 37.5% over one year and down 4.2% over three months. Its 52-week range is ₹7.05 to ₹17.25.
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.